Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation

Scott Solomon, Lizamarie Bachier-Rodriguez, Joseph Maakaron, Katelin Jackson, Xu Zhang, H. Kent Holland, Asad Bashey, Melhem Solh

Blood (2025) 146 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2025-4194

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.

Christopher Graham, Roy Kao, Qing Cao, Punita Grover, Joseph Norton, Cameron McDonald-Hyman, Joseph Maakaron, Jeremy Allred, Veronika Bachanova, Jeffrey Miller, Daniel Weisdorf, Mark Juckett

Blood (2025) 146 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2025-4220

Published: 2025

Journal Articles

Coronary artery calcification and its effect on cardiac events in patients undergoing allogeneic stem cell transplantation using nonmyeloablative conditioning

Christopher Graham, Roy Kao, Qing Cao, Cameron McDonald-Hyman, Joseph Norton, Punita Grover, Joseph Maakaron, Jeremy Allred, Veronika Bachanova, Jeffrey Miller, Daniel Weisdorf, Mark Juckett

Blood (2025) 146 (Supplement 1): 4219.

https://doi.org/10.1182/blood-2025-4219

Published: 2025

Journal Articles

Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation

Dawn Speckhart, Krishi Patel, Jennifer Guevara, Joyce Izundu, Xu Zhang, Scott Solomon, H Kent Holland, Asad Bashey, Joseph Maakaron, Lizamarie Bachier-Rodriguez, Melhem Solh

Blood (2025) 146 (Supplement 1): 2839.

https://doi.org/10.1182/blood-2025-2839

Published: 2025

Journal Articles

Age-related left-digit bias in selection of patients referred for autologous and allogeneic hematopoietic transplantation: An analysis of 877 patients referred to a single center

Asad Bashey, Xu Zhang, H. Kent Holland, Lizamarie Bachier-Rodriguez, Joseph Maakaron, Scott Solomon, Melhem Solh

Blood (2025) 146 (Supplement 1): 6211.

https://doi.org/10.1182/blood-2025-6211

Published: 2025

Journal Articles

Outcomes for allogeneic transplant in myelofibrosis remain suboptimal in the modern era despite increased use of post-transplant cyclophosphamide and pre-transplant JAK inhibition.

Scott Solomon, Joseph Maakaron, Lizamarie Bachier-Rodriguez, Melhem Solh, Katelin Jackson, Xu Zhang, H. Kent Holland, Asad Bashey

Blood (2025) 146 (Supplement 1): 7830.

https://doi.org/10.1182/blood-2025-7830

Published: 2025

Journal Articles

Risk of relapse and mortality after non-myeloablative allogeneic stem cell transplant for Acute Myeloid Leukemia and myelodysplastic syndrome after fludarabine, cyclophosphamide, and 200 centigray total body irradiation with gvhd prophylaxis using post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil: Impact of maintenance chemotherapy

Christopher Graham, Roy Kao, Qing Cao, Cameron McDonald-Hyman, Joseph Norton, Punita Grover, Joseph Maakaron, Jeremy Allred, Veronika Bachanova, Jeffrey Miller, Daniel Weisdorf, Mark Juckett

Blood (2025) 146 (Supplement 1): 7781.

https://doi.org/10.1182/blood-2025-7781

Published: 2025

Journal Articles

Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T

Supriya Gupta, Edmund Waller, Ran Reshef, Vinay Vanguru, Adam Olszewski, Scott Solomon, Joseph Maakaron, Aparna Raval, Sharon Yavrom, John Byon, Bijal Shah

Blood (2025) 146 (Supplement 1): 267.

https://doi.org/10.1182/blood-2025-267

Published: 2025

Journal Articles

Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study

Vijaya Bhatt, Christopher Wichman, Joseph Maakaron, Richard Stone, Moataz Ellithi, Michael Haddadin, Lori Maness, Soroush Mortaz-Hedjri, Steven Green, Kah Poh (Melissa) Loh, Sarah Wall, Krishna Gundabolu

Blood (2025) 146 (Supplement 1): 6381.

https://doi.org/10.1182/blood-2025-6381

Published: 2025

Journal Articles

Incidence, predictors and consequences of poor graft function after post-transplant cyclophosphamide (PTCy)-based allogeneic transplantation

Lizamarie Bachier Rodriguez, Asad Bashey, H. Kent Holland, Melhem Solh, Joseph Maakaron, Katelin Jackson, Xu Zhang, Scott Solomon

Blood (2025) 146 (Supplement 1): 7709.

https://doi.org/10.1182/blood-2025-7709

Published: 2025

Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2024-193896

Published: 2024

Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 3728–3730.

https://doi.org/10.1182/blood-2022-167772

Published: 2022

Journal Articles

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2022) 140 (Supplement 1): 10396–10398.

https://doi.org/10.1182/blood-2022-169689

Published: 2022

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Veronika Bachanova, Livia Hegerova, Qing Cao, Murali Janakiram, Joseph Maakaron, Sabarish Ayyappan, Daniel J. Weisdorf, Jaroslav Zak, Umar Farooq, Vaishalee P. Kenkre

Blood (2021) 138 (Supplement 1): 230.

https://doi.org/10.1182/blood-2021-149675

Published: 2021

Journal Articles

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Joseph Maakaron, Emily Stene, Megan Bruns, Todd E. DeFor, Najla H El Jurdi, Veronika Bachanova, Daniel J. Weisdorf, Jeffrey S. Miller, Murali Janakiram, Mark Juckett

Blood (2021) 138 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2021-149607

Published: 2021

Journal Articles

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Joseph Maakaron, Qiuhong Zhao, Jayalakshmi Panicker Balakrishna, Marcin Puto, Wesley Ferguson, Sam Penza, Jonathan E Brammer, Kami J. Maddocks, Yvonne A. Efebera, Ayman Saad, Samantha Jaglowski, Basem M. William

Blood (2021) 138 (Supplement 1): 656.

https://doi.org/10.1182/blood-2021-149580

Published: 2021

Journal Articles

Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-137589

Published: 2020

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Veronika Bachanova, MD PhD, Joseph Maakaron, MD, David H. McKenna, MD, Qing Cao, MS, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Ronit Simantov, MD, Tracey Lodie, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-142419

Published: 2020

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation

Coronary artery calcification and its effect on cardiac events in patients undergoing allogeneic stem cell transplantation using nonmyeloablative conditioning

Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation

Age-related left-digit bias in selection of patients referred for autologous and allogeneic hematopoietic transplantation: An analysis of 877 patients referred to a single center

Outcomes for allogeneic transplant in myelofibrosis remain suboptimal in the modern era despite increased use of post-transplant cyclophosphamide and pre-transplant JAK inhibition.

Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T

Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study

Incidence, predictors and consequences of poor graft function after post-transplant cyclophosphamide (PTCy)-based allogeneic transplantation

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only